Furthermore, PARP mutations or deletions, replication fork stabilization, suppression of DNA replication gaps, DSB repair pathway changes, epigenetic modifications, pharmacological alterations, and the tumor microenvironment all play significant functions in mediating resistance to PARP inhibitors. Here, PARP1 is linked to neoplasm.